View full meeting coverage »

Eyetube Meeting Coverage:

OIS RETINA 2018

 

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

Spark Therapeutics

  Channels: Retina | Posted 7/23/2018

Paulo Falabella, MD, PhD, Medical Director, Ophthalmology, Spark Therapeutics, talks about the significance of the approval of Luxturna (voretigene neparvovec-rzyl), which was the first gene therapy for an inherited disease approved in the United States.

Luxturna (Spark Therapeutics)


9 / 11 Series: OIS RETINA 2018